Key Highlights
- Shares of Immutep stock skyrocketed more than 101% during Wednesday’s trading session following FDA Orphan Drug Designation approval for eftilagimod alfa (efti).
- The FDA designation applies to treatment of soft tissue sarcoma, a rare form of cancer impacting under 200,000 individuals across the United States.
- Key advantages include tax incentives, waived regulatory fees, specialized FDA guidance, and seven-year market exclusivity upon approval.
- Clinical evidence from the Phase II EFTISARC-NEO study provided the foundation for the FDA’s determination, successfully achieving its primary objective in 38 enrolled patients.
- The announcement arrives on the heels of discontinuing the TACTI-004 Phase III study, a move projected to preserve operating capital through Q2 2027 and beyond.
The Australian biotechnology firm Immutep witnessed its stock valuation more than double this Wednesday following confirmation that the U.S. Food and Drug Administration awarded Orphan Drug Designation (ODD) to its primary oncology candidate, eftilagimod alfa.
Shares traded on the Australian Securities Exchange surged 101.3%, reaching A$0.079 throughout Wednesday’s session.
The federal designation specifically applies to efti’s application in treating soft tissue sarcoma (STS), an uncommon malignancy representing a significant area of unmet therapeutic need within American healthcare.
Receiving ODD status brings substantial commercial and operational advantages: specialized regulatory consultation, eligibility for tax benefits, exemption from certain administrative fees, and a guaranteed seven-year period of market exclusivity should the therapy ultimately secure marketing approval.
The agency’s designation decision relied heavily on clinical evidence generated through the Phase II EFTISARC-NEO investigation. This clinical study evaluated efti combined with radiotherapy alongside Merck’s KEYTRUDA (pembrolizumab) in individuals diagnosed with resectable soft tissue sarcoma prior to surgical intervention.
Among 38 patients whose data could be evaluated, the investigation successfully achieved its primary efficacy measure. Researchers documented a median tumour hyalinization/fibrosis rate reaching 51.5%, substantially surpassing the predetermined threshold of 35% and the historical standard of approximately 15% typically observed with radiation treatment alone.
Positive outcomes were consistent across various sarcoma subtypes. Investigators characterized the treatment’s safety characteristics as encouraging, noting zero instances of surgical delays attributable to the intervention.
TACTI-004 Trial Discontinuation
This encouraging FDA announcement follows closely after Immutep’s decision in early March to discontinue its TACTI-004 Phase III clinical investigation. That particular study was evaluating efti as a first-line therapeutic option for non-small cell lung cancer patients.
An Independent Data Monitoring Committee issued a recommendation to terminate the trial based on futility findings. The organization is currently executing an organized shutdown of TACTI-004 operations.
Immutep indicated that terminating this trial should significantly extend its available financial resources far beyond the company’s prior forecast of Q2 2027.
Development Portfolio and Financial Position
In addition to STS and lung cancer applications, Immutep maintains five distinct LAG-3-focused development programs. Among these initiatives, IMP761 is presently undergoing Phase I evaluation for autoimmune disease indications.
The organization reported a net operating loss totaling A$61.4 million during the 2025 fiscal year, representing an increase from the A$42.7 million loss recorded in 2024.
As a pre-revenue biotechnology enterprise, Immutep will need continued capital infusions to maintain its research operations and clinical development activities.
The company has established collaborative relationships with leading pharmaceutical corporations, including Merck (MSD), to support advancement of its therapeutic pipeline.
The EFTISARC-NEO study results, which formed the evidentiary basis for Wednesday’s FDA designation, incorporated translational research findings aligned with efti’s proposed biological mechanism — immune system activation through LAG-3 engagement.
